|Videos|May 25, 2023

Interview with Rentschler Biopharma's Federico Pollano

KEY LEARNING OBJECTIVES

  • Viewers will gain a clear understanding of Rentschler Biopharma’s US offering currently and in the near future
  • Viewers will understand what sets Rentschler Biopharma apart from other CDMOs in the field
  • Viewers will gain a good feel for what it is like to be a client of Rentschler Biopharma


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.